Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer

For patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (SCCHN) limited therapeutic options exist. Only a subset of patients is suitable for combination chemotherapy regimens. Biweekly docetaxel plus cetuximab might be an alternative option. Thus, we performed this retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Posch, Doris, Fuchs, Hannah, Kornek, Gabriela, Grah, Anja, Pammer, Johannes, Aretin, Marie-Bernadette, Fuereder, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011715/
https://www.ncbi.nlm.nih.gov/pubmed/27597175
http://dx.doi.org/10.1038/srep32946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011715/
https://www.ncbi.nlm.nih.gov/pubmed/27597175
http://dx.doi.org/10.1038/srep32946

Ejemplares similares